,34 These findings raise the possibility that patients with EGFR-mutated NSCLC with PD-L1 TPS ≥50% may benefit from ICI-based combination therapies, particularly those designed to alter the immune milieu. This evidence concerns the gene EGFR and non-small cell lung carcinoma.